Drug development advances in beneficial loss-of-function mutation targets validated by human genetics
by Sichuan International Medical Exchange and Promotion AssociationTargets primarily include PCSK9, ANGPTL3, HSD17B13, KHK, ASGR1, GPR75, CIDEB, and INHBE. Drug types primarily include small molecules
Updated on: March 28,2024
0
Drug development advances in beneficial loss-of-function mutation targets validated by human genetics
by Sichuan International Medical Exchange and Promotion AssociationTargets primarily include PCSK9, ANGPTL3, HSD17B13, KHK, ASGR1, GPR75, CIDEB, and INHBE. Drug types primarily include small molecules
Updated on:March 28,2024
0